Syndax Pharmaceuticals Inc. (SNDX)
SNDX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$13.95
-15.71% on the day
Market cap
$1.2B
Small cap
Revenue · 2025
$172.4M
+627.8% on 2024
Net income · 2025
-$285.4M
-165.6% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | SNDX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2016 |
| SEC CIK | 0001395937 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $172.4M |
| Net income | -$285.4M |
| Operating income | -$273.1M |
| Net margin | -165.6% |
| Operating margin | -158.4% |
| Revenue growth | +627.8% |
| Cash | $134.9M |
| Total assets | $529.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 7.2× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2024-02-27 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-08-04 |
| Latest current report | 8-K | 2026-08-04 |
| Latest proxy | DEFA14A | 2026-06-04 |
Source: SEC EDGAR submissions feed, 653 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -20.0% |
| 1 month | -24.7% |
| 3 months | -40.0% |
| Year to date | -35.1% |
| 1 year | -10.4% |
| From 52-week high | -45.8% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TYRA | Tyra Biosciences Inc. | $18.56 | -5.31% | $1.3B |
| KARD | Kardigan Inc. | $12.97 | -9.62% | $1.2B |
| GHRS | GH Research PLC | $18.85 | -5.84% | $1.3B |
| NKTR | Nektar Therapeutics | $37.92 | -4.82% | $1.3B |
| ORIC | Oric Pharmaceuticals Inc. | $11.31 | -4.23% | $1.2B |
| ANAB | AnaptysBio Inc. | $45.59 | -0.98% | $1.3B |
| BCAX | Bicara Therapeutics Inc. | $17.34 | +0.06% | $1.1B |
| DMRA | Damora Therapeutics Inc. | $18.56 | -8.37% | $1.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier